克唑替尼胶囊联合NP方案治疗晚期非小细胞肺癌患者的疗效

Efficacy of crizotinib capsule combined with NP regimen in the treatment of advanced non-small cell lung cancer patients

目的探讨克唑替尼胶囊联合长春瑞滨+顺铂(NP)方案治疗晚期非小细胞肺癌患者的疗效。方法将104例晚期非小细胞肺癌患者根据治疗方式的不同分为NP组(n=51)和克唑替尼组(n=53)。NP组患者采取NP方案治疗,克唑替尼组患者在NP组的基础上联合克唑替尼胶囊治疗。比较两组患者疗效、血清肿瘤标志物、免疫功能指标及不良反应发生情况。结果克唑替尼组患者总有效率明显高于NP组,差异有统计学意义(P﹤0.01)。治疗后,两组患者癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)水平均较治疗前降低,且克唑替尼组患者NSE、CEA、CYFRA21-1水平均低于NP组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平均较治疗前升高,CD8^(+)水平均较治疗前降低,且克唑替尼组患者CD3^(+)、CD4^(+)、CD8^(+)水平均高于NP组,差异均有统计学意义(P﹤0.05)。两组患者不良反应发生率比较,差异无统计学意义(P﹥0.05)。结论克唑替尼胶囊联合NP方案可提高晚期非小细胞肺癌患者临床疗效,降低血清肿瘤标志物水平,改善患者免疫功能,且不增加不良反应。

Objective To investigate the efficacy of crizotinib capsule combined with vinorelbine+cisplatin(NP)regimen in the treatment of advanced non-small cell lung cancer.Method A total of 104 patients with advanced non-small cell lung cancer were divided into NP group(n=51)and crizotinib group(n=53).Patients in NP group were treated with NP regimen,and patients in crizotinib group were treated with crizotinib capsule on the basis of NP group.The efficacy,serum tumor markers,immune function indexes and the incidence of adverse reactions were compared between the two groups.Result The total effective rate of crizotinib group was significantly higher than that of NP group,the difference was statistically significant(P<0.01).After treatment,the levels of carcinoembryonic antigen(CEA),neuronal specific enolase(NSE)and cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)in both groups were lower than those before treatment,and the levels of NSE,CEA and CYFRA21-1 in crizotinib group were lower than those in NP group,the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)in two groups were higher than those before treatment,the levels of CD8^(+)in two groups were lower than those before treatment,and the levels of CD3^(+),CD4^(+)and CD8^(+)in crizotinib group were higher than those in NP group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Crizotinib capsule combined with NP regimen can improve the clinical efficacy of advanced non-small cell lung cancer patients,reduce the level of serum tumor markers,improve the immune function,and do not increase adverse reactions.